SlideShare a Scribd company logo
Development of double stand break assessment assay with HCS by
using the HepG2 cell line and evaluation with primary skin cell (NHEK)
M. ROUDAUT1, S. ASTRI2, N. ORSINI2, A.-P. LUZY2*, J. BURSZTYKA1* & N. MAUBON1
1 HCS Pharma, Biopôle, 6 rue Pierre Joseph Colin, 35000 Rennes
1* julian.bursztyka@hcs-pharma.com
2 Galderma R&D, Les Templiers, 2400 route des Colles, 06410 Biot
²*anne-pascale.luzy@galderma.com
Abstract
The creation of a double strand break (DSB) is accompanied by the phosphorylation of histone H2AX. The measurement of serine 139
phosphorylated histone H2AX (γH2AX) is reported to be a marker of interest to identify potential genotoxic activity.
In order to evaluate the High Content Screening for γH2AX detection, 4 non genotoxic compounds and 9 genotoxic compounds from the
ECVAM list I or II were selected to to be tested on HepG2 cell line. These cells offer the advantage to have H2AX expression data in the
literature. In parallel, Human primary keratinocytes were included. Indeed these cells would be relevant for investigating skin adverse effects
of topical applied xenobiotics with the advantage of High content imaging as valuable tool for screening in the early discovery phase.
Methods
Conclusions & Perspectives
Cell culture: HepG2 were routinely maintained in MEM supplemented with 10% FBS, 1% non essential amino-acids, 1% peni/strepto and 1% L-glutamine. Neonatal human epidermal keratinocytes
(NHEK, pool of donors) were obtained and cultured following the recommendations from Lonza. Cells were seeded at 10 000 cells/well for HepG2 and 5 000 cells/well for NHEK in 96-well plates
(Greiner® advanced TC µClear). The cells were then incubated overnight at 37 °C in 5 % CO2 before treatment.
Genotoxic drugs exposure: 16 compounds were assessed for their DSBs inducing properties: Etoposide, azidothymidine (AZT), mitomycine C (MMC), vinblastin, taxol, colchicine, methylmethane
sulfonate (MMS), N-ethyl-N-nitrosourea (ENU), Cisplatin, 4-nitroquinoline-N-oxide (4NQO), Phenformin, cadmium chloride, hydroquinone, D-mannitol, ampicilline & n-butyl chloride. Exposure of the
cells was performed by replacement of the medium in each well with fresh medium with or without the different genotoxic agents at different concentrations ranging from 0.195 µM to 100 µM, except
for MMS and ENU (1.563 to 1000µM). Benzo-[a]-pyren (BaP, 10µM, genotoxic only if metabolized) and MMC (10µM) were used as positive controls. Incubations were done in duplicate.
Assessment of double strand breaks through γH2AX detection: Cells were paraformaldehyde fixed (4%) after 24h of exposure. After permeabilisation of the cells by PBS/Tween20, staining was done by
adding anti-γH2AX (phospho ser139) antibody (Abcam) followed by secondary antibody conjugated with Alexa-488. Nuclei were counterstained with Hoechst 33348. Imaging was done on an Operetta
(Perkin Elmer) with a 20x objective. Image analysis was performed with Columbus software (Perkin Elmer). Relative cell count (RCC) was calculated as a percentage of the cell count in the control (0.5%
DMSO). For γH2AX Results are expressed as a fold change of the mean intensity in the nucleus γH2AX intensity is significantly higher than the untreated cells.
To get this poster,
please flash the QR-
code
You can use the
I-NIGMA application
from your store
 Evaluation of γH2AX by HCS on HepG2 and Primary Human keratinocytes cells seems to be a promising technology.
 On Primary Human keratinocytes different technical aspect have to be improved (i.e. cell synchronization) to generate robust results and
more compounds have to be tested.
 The RCC cut off and the γH2AX positive threshold have to be accurately defined.
 Further work is needed on both cell types to fully validate the use of HCS for γH2AX assessment.
Results
Fig. 1: Inter and intra plate variability on HepG2 cells.
Fig. 2: Genotoxicity (γH2AX ) and cytotoxicity (RCC) assessment on HepG2 cells.
Example of data.
Fig. 3: Comparison of the sensitivity and specificity of HepG2 as a cellular
model to screen compounds for their DSBs inducing properties.
Fig. 4: Development of this assay on human primary keratinocytes.
Fig. 5: Nuclei of primary human epidermal
keratinocytes exposed to etoposide 6.25µM for 24h.
Blue : Hoechst staining. Green : γH2AX staining (a).
Red: 53BP1 staining (b). P53 binding protein 1 is
involved in the DSBs repair process, thus colocalising
with γH2AX (c : merged images).
a b c

More Related Content

What's hot

Fluorescence activated cell sorted assay for Gaucher's disease
Fluorescence activated cell sorted assay for Gaucher's diseaseFluorescence activated cell sorted assay for Gaucher's disease
Fluorescence activated cell sorted assay for Gaucher's disease
Mayank Sagar
 
Improved vector design eases cell line development workflow in the CHOZN GS-/...
Improved vector design eases cell line development workflow in the CHOZN GS-/...Improved vector design eases cell line development workflow in the CHOZN GS-/...
Improved vector design eases cell line development workflow in the CHOZN GS-/...
Merck Life Sciences
 
GCPALS - Summer Research Poster Template 1
GCPALS - Summer Research Poster Template 1GCPALS - Summer Research Poster Template 1
GCPALS - Summer Research Poster Template 1Sarah Bailey
 
Collaborative science to identify novel inhibitors for the pseudokinase TRIB2
Collaborative science to identify novel inhibitors for the pseudokinase TRIB2Collaborative science to identify novel inhibitors for the pseudokinase TRIB2
Collaborative science to identify novel inhibitors for the pseudokinase TRIB2Morgan Focas
 
Fall2014_ResearchPoster_CodyHeiser
Fall2014_ResearchPoster_CodyHeiserFall2014_ResearchPoster_CodyHeiser
Fall2014_ResearchPoster_CodyHeiserCody Heiser
 
Mol Cancer Ther-2010-Marcu-180-9
Mol Cancer Ther-2010-Marcu-180-9Mol Cancer Ther-2010-Marcu-180-9
Mol Cancer Ther-2010-Marcu-180-9Jahan Marcu, Ph.D
 
Ph D Swati Dhar
Ph D Swati DharPh D Swati Dhar
Ph D Swati Dhar
Swati Dhar
 
The Effects of Ibrutinib on Anti Apoptotic Proteins in PTLD
The Effects of Ibrutinib on Anti Apoptotic Proteins in PTLDThe Effects of Ibrutinib on Anti Apoptotic Proteins in PTLD
The Effects of Ibrutinib on Anti Apoptotic Proteins in PTLD
NikitaSall1
 
Immunoprotective response
Immunoprotective responseImmunoprotective response
Immunoprotective response
Ayush Jain
 
DNA damage repair Neil3 gene Knockout in MOLT-4
DNA damage repair Neil3 gene Knockout in MOLT-4DNA damage repair Neil3 gene Knockout in MOLT-4
DNA damage repair Neil3 gene Knockout in MOLT-4
iosrjce
 
PharmacyResearchDay_Yue.Chang_2016.final
PharmacyResearchDay_Yue.Chang_2016.finalPharmacyResearchDay_Yue.Chang_2016.final
PharmacyResearchDay_Yue.Chang_2016.finalEnoch Yue
 
Eddie Senior Seminar! 1
Eddie Senior Seminar! 1Eddie Senior Seminar! 1
Eddie Senior Seminar! 1eddie moat
 
Improved Platforms for CHO Cell Line Development
Improved Platforms for CHO Cell Line Development  Improved Platforms for CHO Cell Line Development
Improved Platforms for CHO Cell Line Development
Merck Life Sciences
 
Pells et al [2015] PLoS ONE 10[7] e0131102
Pells et al [2015] PLoS ONE 10[7] e0131102Pells et al [2015] PLoS ONE 10[7] e0131102
Pells et al [2015] PLoS ONE 10[7] e0131102Steve Pells
 

What's hot (19)

Vumc poster
Vumc posterVumc poster
Vumc poster
 
Fluorescence activated cell sorted assay for Gaucher's disease
Fluorescence activated cell sorted assay for Gaucher's diseaseFluorescence activated cell sorted assay for Gaucher's disease
Fluorescence activated cell sorted assay for Gaucher's disease
 
Improved vector design eases cell line development workflow in the CHOZN GS-/...
Improved vector design eases cell line development workflow in the CHOZN GS-/...Improved vector design eases cell line development workflow in the CHOZN GS-/...
Improved vector design eases cell line development workflow in the CHOZN GS-/...
 
GCPALS - Summer Research Poster Template 1
GCPALS - Summer Research Poster Template 1GCPALS - Summer Research Poster Template 1
GCPALS - Summer Research Poster Template 1
 
Collaborative science to identify novel inhibitors for the pseudokinase TRIB2
Collaborative science to identify novel inhibitors for the pseudokinase TRIB2Collaborative science to identify novel inhibitors for the pseudokinase TRIB2
Collaborative science to identify novel inhibitors for the pseudokinase TRIB2
 
Fall2014_ResearchPoster_CodyHeiser
Fall2014_ResearchPoster_CodyHeiserFall2014_ResearchPoster_CodyHeiser
Fall2014_ResearchPoster_CodyHeiser
 
Mol Cancer Ther-2010-Marcu-180-9
Mol Cancer Ther-2010-Marcu-180-9Mol Cancer Ther-2010-Marcu-180-9
Mol Cancer Ther-2010-Marcu-180-9
 
Peptides 2013 Rideout
Peptides 2013 RideoutPeptides 2013 Rideout
Peptides 2013 Rideout
 
Ph D Swati Dhar
Ph D Swati DharPh D Swati Dhar
Ph D Swati Dhar
 
ganzyme PDF.pdf
ganzyme PDF.pdfganzyme PDF.pdf
ganzyme PDF.pdf
 
The Effects of Ibrutinib on Anti Apoptotic Proteins in PTLD
The Effects of Ibrutinib on Anti Apoptotic Proteins in PTLDThe Effects of Ibrutinib on Anti Apoptotic Proteins in PTLD
The Effects of Ibrutinib on Anti Apoptotic Proteins in PTLD
 
Immunoprotective response
Immunoprotective responseImmunoprotective response
Immunoprotective response
 
DNA damage repair Neil3 gene Knockout in MOLT-4
DNA damage repair Neil3 gene Knockout in MOLT-4DNA damage repair Neil3 gene Knockout in MOLT-4
DNA damage repair Neil3 gene Knockout in MOLT-4
 
PharmacyResearchDay_Yue.Chang_2016.final
PharmacyResearchDay_Yue.Chang_2016.finalPharmacyResearchDay_Yue.Chang_2016.final
PharmacyResearchDay_Yue.Chang_2016.final
 
Eddie Senior Seminar! 1
Eddie Senior Seminar! 1Eddie Senior Seminar! 1
Eddie Senior Seminar! 1
 
Improved Platforms for CHO Cell Line Development
Improved Platforms for CHO Cell Line Development  Improved Platforms for CHO Cell Line Development
Improved Platforms for CHO Cell Line Development
 
Pells et al [2015] PLoS ONE 10[7] e0131102
Pells et al [2015] PLoS ONE 10[7] e0131102Pells et al [2015] PLoS ONE 10[7] e0131102
Pells et al [2015] PLoS ONE 10[7] e0131102
 
Fulltext
FulltextFulltext
Fulltext
 
Final Version of Poster for Exeter
Final Version of Poster for ExeterFinal Version of Poster for Exeter
Final Version of Poster for Exeter
 

Similar to Poster - Development of double stand break assessment assay with HCS by using the HepG2 cell line and evaluation with primary skin cell (NHEK)

Use of Automated High Content Analysis Applied To Assessment Of Primary DNA D...
Use of Automated High Content Analysis Applied To Assessment Of Primary DNA D...Use of Automated High Content Analysis Applied To Assessment Of Primary DNA D...
Use of Automated High Content Analysis Applied To Assessment Of Primary DNA D...
HCS Pharma
 
HepG2 cell model for genotoxicity and steatosis assessment
HepG2 cell model for genotoxicity and steatosis assessmentHepG2 cell model for genotoxicity and steatosis assessment
HepG2 cell model for genotoxicity and steatosis assessment
HCS Pharma
 
Genotoxicity assays: assessment of double strand breaks through phospho-H2AX ...
Genotoxicity assays: assessment of double strand breaks through phospho-H2AX ...Genotoxicity assays: assessment of double strand breaks through phospho-H2AX ...
Genotoxicity assays: assessment of double strand breaks through phospho-H2AX ...
HCS Pharma
 
Multiplex energy metabolism
Multiplex energy metabolismMultiplex energy metabolism
Multiplex energy metabolism
Matt Sanderson
 
immunohistochemically and in situ hybridizati.pptx
immunohistochemically and in situ hybridizati.pptximmunohistochemically and in situ hybridizati.pptx
immunohistochemically and in situ hybridizati.pptx
Marwa972783
 
immunohistochemically and in situ hybridizati.pptx
immunohistochemically and in situ hybridizati.pptximmunohistochemically and in situ hybridizati.pptx
immunohistochemically and in situ hybridizati.pptx
Marwa972783
 
Silencing c-Myc translation as a therapeutic strategy through targeting PI3Kd...
Silencing c-Myc translation as a therapeutic strategy through targeting PI3Kd...Silencing c-Myc translation as a therapeutic strategy through targeting PI3Kd...
Silencing c-Myc translation as a therapeutic strategy through targeting PI3Kd...Mark Lipstein
 
Poster_RosanaLopez_SULI_Summer2011_aug8_final_2
Poster_RosanaLopez_SULI_Summer2011_aug8_final_2Poster_RosanaLopez_SULI_Summer2011_aug8_final_2
Poster_RosanaLopez_SULI_Summer2011_aug8_final_2Rosana Lopez
 
Imaginal discs1
Imaginal discs1Imaginal discs1
Imaginal discs1
Prerna Jain
 
Ejmc cancer
Ejmc cancerEjmc cancer
Ejmc cancer
Dr. Syed Ovais
 
Generation of MRP2 Efflux Transporter Knock-Out in HepaRG Cell Line
Generation of MRP2 Efflux Transporter Knock-Out in HepaRG Cell LineGeneration of MRP2 Efflux Transporter Knock-Out in HepaRG Cell Line
Generation of MRP2 Efflux Transporter Knock-Out in HepaRG Cell Line
mdmitc
 
Universal and rapid salt extraction of high quality genomic dna for pcr-based...
Universal and rapid salt extraction of high quality genomic dna for pcr-based...Universal and rapid salt extraction of high quality genomic dna for pcr-based...
Universal and rapid salt extraction of high quality genomic dna for pcr-based...CAS0609
 
Petrak Toman Et Al Proteomics 2009
Petrak Toman Et Al Proteomics 2009Petrak Toman Et Al Proteomics 2009
Petrak Toman Et Al Proteomics 2009onia35
 
AACR poster VP_2014
AACR poster VP_2014AACR poster VP_2014
AACR poster VP_2014Victor Prima
 
IN VITRO EVALUATION OF CYTOTOXIC ACTIVITY OF HYDRAZIDEHYDRAZONES BASED ON 4-C...
IN VITRO EVALUATION OF CYTOTOXIC ACTIVITY OF HYDRAZIDEHYDRAZONES BASED ON 4-C...IN VITRO EVALUATION OF CYTOTOXIC ACTIVITY OF HYDRAZIDEHYDRAZONES BASED ON 4-C...
IN VITRO EVALUATION OF CYTOTOXIC ACTIVITY OF HYDRAZIDEHYDRAZONES BASED ON 4-C...Dimo Angelov
 

Similar to Poster - Development of double stand break assessment assay with HCS by using the HepG2 cell line and evaluation with primary skin cell (NHEK) (20)

Use of Automated High Content Analysis Applied To Assessment Of Primary DNA D...
Use of Automated High Content Analysis Applied To Assessment Of Primary DNA D...Use of Automated High Content Analysis Applied To Assessment Of Primary DNA D...
Use of Automated High Content Analysis Applied To Assessment Of Primary DNA D...
 
HepG2 cell model for genotoxicity and steatosis assessment
HepG2 cell model for genotoxicity and steatosis assessmentHepG2 cell model for genotoxicity and steatosis assessment
HepG2 cell model for genotoxicity and steatosis assessment
 
Genotoxicity assays: assessment of double strand breaks through phospho-H2AX ...
Genotoxicity assays: assessment of double strand breaks through phospho-H2AX ...Genotoxicity assays: assessment of double strand breaks through phospho-H2AX ...
Genotoxicity assays: assessment of double strand breaks through phospho-H2AX ...
 
Multiplex energy metabolism
Multiplex energy metabolismMultiplex energy metabolism
Multiplex energy metabolism
 
BBRC ndrg2
BBRC ndrg2BBRC ndrg2
BBRC ndrg2
 
2014 Zorniak JNS
2014 Zorniak JNS2014 Zorniak JNS
2014 Zorniak JNS
 
immunohistochemically and in situ hybridizati.pptx
immunohistochemically and in situ hybridizati.pptximmunohistochemically and in situ hybridizati.pptx
immunohistochemically and in situ hybridizati.pptx
 
immunohistochemically and in situ hybridizati.pptx
immunohistochemically and in situ hybridizati.pptximmunohistochemically and in situ hybridizati.pptx
immunohistochemically and in situ hybridizati.pptx
 
Silencing c-Myc translation as a therapeutic strategy through targeting PI3Kd...
Silencing c-Myc translation as a therapeutic strategy through targeting PI3Kd...Silencing c-Myc translation as a therapeutic strategy through targeting PI3Kd...
Silencing c-Myc translation as a therapeutic strategy through targeting PI3Kd...
 
Poster_RosanaLopez_SULI_Summer2011_aug8_final_2
Poster_RosanaLopez_SULI_Summer2011_aug8_final_2Poster_RosanaLopez_SULI_Summer2011_aug8_final_2
Poster_RosanaLopez_SULI_Summer2011_aug8_final_2
 
Lepow Day Poster 2
Lepow Day Poster 2Lepow Day Poster 2
Lepow Day Poster 2
 
Imaginal discs1
Imaginal discs1Imaginal discs1
Imaginal discs1
 
Ejmc cancer
Ejmc cancerEjmc cancer
Ejmc cancer
 
Generation of MRP2 Efflux Transporter Knock-Out in HepaRG Cell Line
Generation of MRP2 Efflux Transporter Knock-Out in HepaRG Cell LineGeneration of MRP2 Efflux Transporter Knock-Out in HepaRG Cell Line
Generation of MRP2 Efflux Transporter Knock-Out in HepaRG Cell Line
 
Universal and rapid salt extraction of high quality genomic dna for pcr-based...
Universal and rapid salt extraction of high quality genomic dna for pcr-based...Universal and rapid salt extraction of high quality genomic dna for pcr-based...
Universal and rapid salt extraction of high quality genomic dna for pcr-based...
 
SW_2016_Snehal
SW_2016_SnehalSW_2016_Snehal
SW_2016_Snehal
 
Petrak Toman Et Al Proteomics 2009
Petrak Toman Et Al Proteomics 2009Petrak Toman Et Al Proteomics 2009
Petrak Toman Et Al Proteomics 2009
 
Poster
PosterPoster
Poster
 
AACR poster VP_2014
AACR poster VP_2014AACR poster VP_2014
AACR poster VP_2014
 
IN VITRO EVALUATION OF CYTOTOXIC ACTIVITY OF HYDRAZIDEHYDRAZONES BASED ON 4-C...
IN VITRO EVALUATION OF CYTOTOXIC ACTIVITY OF HYDRAZIDEHYDRAZONES BASED ON 4-C...IN VITRO EVALUATION OF CYTOTOXIC ACTIVITY OF HYDRAZIDEHYDRAZONES BASED ON 4-C...
IN VITRO EVALUATION OF CYTOTOXIC ACTIVITY OF HYDRAZIDEHYDRAZONES BASED ON 4-C...
 

More from HCS Pharma

Poster HCSPHARMA (OncoLilleDays2022) - Mechanobiological characterization of ...
Poster HCSPHARMA (OncoLilleDays2022) - Mechanobiological characterization of ...Poster HCSPHARMA (OncoLilleDays2022) - Mechanobiological characterization of ...
Poster HCSPHARMA (OncoLilleDays2022) - Mechanobiological characterization of ...
HCS Pharma
 
Poster : Development of personalized therapeutic targeting in lung cancer wit...
Poster : Development of personalized therapeutic targeting in lung cancer wit...Poster : Development of personalized therapeutic targeting in lung cancer wit...
Poster : Development of personalized therapeutic targeting in lung cancer wit...
HCS Pharma
 
Poster - Including the matricial tumoral microenvironment in 3D in vitro mode...
Poster - Including the matricial tumoral microenvironment in 3D in vitro mode...Poster - Including the matricial tumoral microenvironment in 3D in vitro mode...
Poster - Including the matricial tumoral microenvironment in 3D in vitro mode...
HCS Pharma
 
HCS PHARMA - (ECM 2022) Development of innovative hiPSC-based model including...
HCS PHARMA - (ECM 2022) Development of innovative hiPSC-based model including...HCS PHARMA - (ECM 2022) Development of innovative hiPSC-based model including...
HCS PHARMA - (ECM 2022) Development of innovative hiPSC-based model including...
HCS Pharma
 
HCSPHARMA Importance of microenvironment in cerebral in vitro models for phen...
HCSPHARMA Importance of microenvironment in cerebral in vitro models for phen...HCSPHARMA Importance of microenvironment in cerebral in vitro models for phen...
HCSPHARMA Importance of microenvironment in cerebral in vitro models for phen...
HCS Pharma
 
Poster - A single procedure to generate functional hiPSCs-derived liver organ...
Poster - A single procedure to generate functional hiPSCs-derived liver organ...Poster - A single procedure to generate functional hiPSCs-derived liver organ...
Poster - A single procedure to generate functional hiPSCs-derived liver organ...
HCS Pharma
 
Poster - BIOMIMESYS® 3D hydroscaffold a matricial microenvironment for physio...
Poster - BIOMIMESYS® 3D hydroscaffold a matricial microenvironment for physio...Poster - BIOMIMESYS® 3D hydroscaffold a matricial microenvironment for physio...
Poster - BIOMIMESYS® 3D hydroscaffold a matricial microenvironment for physio...
HCS Pharma
 
BIOMIMESYS® Liver
BIOMIMESYS® LiverBIOMIMESYS® Liver
BIOMIMESYS® Liver
HCS Pharma
 
BIOMIMESYS® Adipose tissue
BIOMIMESYS® Adipose tissueBIOMIMESYS® Adipose tissue
BIOMIMESYS® Adipose tissue
HCS Pharma
 
BIOMIMESYS® Oncology
BIOMIMESYS® OncologyBIOMIMESYS® Oncology
BIOMIMESYS® Oncology
HCS Pharma
 
Importance of matricial and cellular microenvironments in in vitro models for...
Importance of matricial and cellular microenvironments in in vitro models for...Importance of matricial and cellular microenvironments in in vitro models for...
Importance of matricial and cellular microenvironments in in vitro models for...
HCS Pharma
 
Simplifying 3d cell culture generation for high content screening with BIOMIM...
Simplifying 3d cell culture generation for high content screening with BIOMIM...Simplifying 3d cell culture generation for high content screening with BIOMIM...
Simplifying 3d cell culture generation for high content screening with BIOMIM...
HCS Pharma
 
BIOMIMESYS®Liver, a 3D cell culture model for maintaining and promoting hepat...
BIOMIMESYS®Liver, a 3D cell culture model for maintaining and promoting hepat...BIOMIMESYS®Liver, a 3D cell culture model for maintaining and promoting hepat...
BIOMIMESYS®Liver, a 3D cell culture model for maintaining and promoting hepat...
HCS Pharma
 
Abstract : a single procedure to generate functional hi ps cs-derived liver o...
Abstract : a single procedure to generate functional hi ps cs-derived liver o...Abstract : a single procedure to generate functional hi ps cs-derived liver o...
Abstract : a single procedure to generate functional hi ps cs-derived liver o...
HCS Pharma
 
Poster – Development and automation of 3D innovative hiPSC-based liver organo...
Poster – Development and automation of 3D innovative hiPSC-based liver organo...Poster – Development and automation of 3D innovative hiPSC-based liver organo...
Poster – Development and automation of 3D innovative hiPSC-based liver organo...
HCS Pharma
 
Poster – Development and automation of 3D innovative hiPSC-based liver organo...
Poster – Development	and	automation of 3D innovative	hiPSC-based liver organo...Poster – Development	and	automation of 3D innovative	hiPSC-based liver organo...
Poster – Development and automation of 3D innovative hiPSC-based liver organo...
HCS Pharma
 
Development of a new liver-on-chip including BIOMIMESYS® technology for mimic...
Development of a new liver-on-chip including BIOMIMESYS® technology for mimic...Development of a new liver-on-chip including BIOMIMESYS® technology for mimic...
Development of a new liver-on-chip including BIOMIMESYS® technology for mimic...
HCS Pharma
 
HCS Pharma complète sa gamme de culture cellulaire en 3D BIOMIMESYS® avec BIO...
HCS Pharma complète sa gamme de culture cellulaire en 3D BIOMIMESYS® avec BIO...HCS Pharma complète sa gamme de culture cellulaire en 3D BIOMIMESYS® avec BIO...
HCS Pharma complète sa gamme de culture cellulaire en 3D BIOMIMESYS® avec BIO...
HCS Pharma
 
HCS Pharma extends its 3D cell culture range BIOMIMESYS® with BIOMIMESYS® Brain
HCS Pharma extends its 3D cell culture range BIOMIMESYS® with BIOMIMESYS® BrainHCS Pharma extends its 3D cell culture range BIOMIMESYS® with BIOMIMESYS® Brain
HCS Pharma extends its 3D cell culture range BIOMIMESYS® with BIOMIMESYS® Brain
HCS Pharma
 
A groundbreaking 3D cell culture technology for HCS: BIOMIMESYS hydroscaffold
A groundbreaking 3D cell culture technology for HCS: BIOMIMESYS hydroscaffoldA groundbreaking 3D cell culture technology for HCS: BIOMIMESYS hydroscaffold
A groundbreaking 3D cell culture technology for HCS: BIOMIMESYS hydroscaffold
HCS Pharma
 

More from HCS Pharma (20)

Poster HCSPHARMA (OncoLilleDays2022) - Mechanobiological characterization of ...
Poster HCSPHARMA (OncoLilleDays2022) - Mechanobiological characterization of ...Poster HCSPHARMA (OncoLilleDays2022) - Mechanobiological characterization of ...
Poster HCSPHARMA (OncoLilleDays2022) - Mechanobiological characterization of ...
 
Poster : Development of personalized therapeutic targeting in lung cancer wit...
Poster : Development of personalized therapeutic targeting in lung cancer wit...Poster : Development of personalized therapeutic targeting in lung cancer wit...
Poster : Development of personalized therapeutic targeting in lung cancer wit...
 
Poster - Including the matricial tumoral microenvironment in 3D in vitro mode...
Poster - Including the matricial tumoral microenvironment in 3D in vitro mode...Poster - Including the matricial tumoral microenvironment in 3D in vitro mode...
Poster - Including the matricial tumoral microenvironment in 3D in vitro mode...
 
HCS PHARMA - (ECM 2022) Development of innovative hiPSC-based model including...
HCS PHARMA - (ECM 2022) Development of innovative hiPSC-based model including...HCS PHARMA - (ECM 2022) Development of innovative hiPSC-based model including...
HCS PHARMA - (ECM 2022) Development of innovative hiPSC-based model including...
 
HCSPHARMA Importance of microenvironment in cerebral in vitro models for phen...
HCSPHARMA Importance of microenvironment in cerebral in vitro models for phen...HCSPHARMA Importance of microenvironment in cerebral in vitro models for phen...
HCSPHARMA Importance of microenvironment in cerebral in vitro models for phen...
 
Poster - A single procedure to generate functional hiPSCs-derived liver organ...
Poster - A single procedure to generate functional hiPSCs-derived liver organ...Poster - A single procedure to generate functional hiPSCs-derived liver organ...
Poster - A single procedure to generate functional hiPSCs-derived liver organ...
 
Poster - BIOMIMESYS® 3D hydroscaffold a matricial microenvironment for physio...
Poster - BIOMIMESYS® 3D hydroscaffold a matricial microenvironment for physio...Poster - BIOMIMESYS® 3D hydroscaffold a matricial microenvironment for physio...
Poster - BIOMIMESYS® 3D hydroscaffold a matricial microenvironment for physio...
 
BIOMIMESYS® Liver
BIOMIMESYS® LiverBIOMIMESYS® Liver
BIOMIMESYS® Liver
 
BIOMIMESYS® Adipose tissue
BIOMIMESYS® Adipose tissueBIOMIMESYS® Adipose tissue
BIOMIMESYS® Adipose tissue
 
BIOMIMESYS® Oncology
BIOMIMESYS® OncologyBIOMIMESYS® Oncology
BIOMIMESYS® Oncology
 
Importance of matricial and cellular microenvironments in in vitro models for...
Importance of matricial and cellular microenvironments in in vitro models for...Importance of matricial and cellular microenvironments in in vitro models for...
Importance of matricial and cellular microenvironments in in vitro models for...
 
Simplifying 3d cell culture generation for high content screening with BIOMIM...
Simplifying 3d cell culture generation for high content screening with BIOMIM...Simplifying 3d cell culture generation for high content screening with BIOMIM...
Simplifying 3d cell culture generation for high content screening with BIOMIM...
 
BIOMIMESYS®Liver, a 3D cell culture model for maintaining and promoting hepat...
BIOMIMESYS®Liver, a 3D cell culture model for maintaining and promoting hepat...BIOMIMESYS®Liver, a 3D cell culture model for maintaining and promoting hepat...
BIOMIMESYS®Liver, a 3D cell culture model for maintaining and promoting hepat...
 
Abstract : a single procedure to generate functional hi ps cs-derived liver o...
Abstract : a single procedure to generate functional hi ps cs-derived liver o...Abstract : a single procedure to generate functional hi ps cs-derived liver o...
Abstract : a single procedure to generate functional hi ps cs-derived liver o...
 
Poster – Development and automation of 3D innovative hiPSC-based liver organo...
Poster – Development and automation of 3D innovative hiPSC-based liver organo...Poster – Development and automation of 3D innovative hiPSC-based liver organo...
Poster – Development and automation of 3D innovative hiPSC-based liver organo...
 
Poster – Development and automation of 3D innovative hiPSC-based liver organo...
Poster – Development	and	automation of 3D innovative	hiPSC-based liver organo...Poster – Development	and	automation of 3D innovative	hiPSC-based liver organo...
Poster – Development and automation of 3D innovative hiPSC-based liver organo...
 
Development of a new liver-on-chip including BIOMIMESYS® technology for mimic...
Development of a new liver-on-chip including BIOMIMESYS® technology for mimic...Development of a new liver-on-chip including BIOMIMESYS® technology for mimic...
Development of a new liver-on-chip including BIOMIMESYS® technology for mimic...
 
HCS Pharma complète sa gamme de culture cellulaire en 3D BIOMIMESYS® avec BIO...
HCS Pharma complète sa gamme de culture cellulaire en 3D BIOMIMESYS® avec BIO...HCS Pharma complète sa gamme de culture cellulaire en 3D BIOMIMESYS® avec BIO...
HCS Pharma complète sa gamme de culture cellulaire en 3D BIOMIMESYS® avec BIO...
 
HCS Pharma extends its 3D cell culture range BIOMIMESYS® with BIOMIMESYS® Brain
HCS Pharma extends its 3D cell culture range BIOMIMESYS® with BIOMIMESYS® BrainHCS Pharma extends its 3D cell culture range BIOMIMESYS® with BIOMIMESYS® Brain
HCS Pharma extends its 3D cell culture range BIOMIMESYS® with BIOMIMESYS® Brain
 
A groundbreaking 3D cell culture technology for HCS: BIOMIMESYS hydroscaffold
A groundbreaking 3D cell culture technology for HCS: BIOMIMESYS hydroscaffoldA groundbreaking 3D cell culture technology for HCS: BIOMIMESYS hydroscaffold
A groundbreaking 3D cell culture technology for HCS: BIOMIMESYS hydroscaffold
 

Recently uploaded

CADAVER AS OUR FIRST TEACHER anatomt in your.pptx
CADAVER AS OUR FIRST TEACHER anatomt in your.pptxCADAVER AS OUR FIRST TEACHER anatomt in your.pptx
CADAVER AS OUR FIRST TEACHER anatomt in your.pptx
fakeloginn69
 
Evgen Osmak: Methods of key project parameters estimation: from the shaman-in...
Evgen Osmak: Methods of key project parameters estimation: from the shaman-in...Evgen Osmak: Methods of key project parameters estimation: from the shaman-in...
Evgen Osmak: Methods of key project parameters estimation: from the shaman-in...
Lviv Startup Club
 
FINAL PRESENTATION.pptx12143241324134134
FINAL PRESENTATION.pptx12143241324134134FINAL PRESENTATION.pptx12143241324134134
FINAL PRESENTATION.pptx12143241324134134
LR1709MUSIC
 
Authentically Social Presented by Corey Perlman
Authentically Social Presented by Corey PerlmanAuthentically Social Presented by Corey Perlman
Authentically Social Presented by Corey Perlman
Corey Perlman, Social Media Speaker and Consultant
 
Maksym Vyshnivetskyi: PMO Quality Management (UA)
Maksym Vyshnivetskyi: PMO Quality Management (UA)Maksym Vyshnivetskyi: PMO Quality Management (UA)
Maksym Vyshnivetskyi: PMO Quality Management (UA)
Lviv Startup Club
 
RMD24 | Debunking the non-endemic revenue myth Marvin Vacquier Droop | First ...
RMD24 | Debunking the non-endemic revenue myth Marvin Vacquier Droop | First ...RMD24 | Debunking the non-endemic revenue myth Marvin Vacquier Droop | First ...
RMD24 | Debunking the non-endemic revenue myth Marvin Vacquier Droop | First ...
BBPMedia1
 
Enterprise Excellence is Inclusive Excellence.pdf
Enterprise Excellence is Inclusive Excellence.pdfEnterprise Excellence is Inclusive Excellence.pdf
Enterprise Excellence is Inclusive Excellence.pdf
KaiNexus
 
Creative Web Design Company in Singapore
Creative Web Design Company in SingaporeCreative Web Design Company in Singapore
Creative Web Design Company in Singapore
techboxsqauremedia
 
3.0 Project 2_ Developing My Brand Identity Kit.pptx
3.0 Project 2_ Developing My Brand Identity Kit.pptx3.0 Project 2_ Developing My Brand Identity Kit.pptx
3.0 Project 2_ Developing My Brand Identity Kit.pptx
tanyjahb
 
LA HUG - Video Testimonials with Chynna Morgan - June 2024
LA HUG - Video Testimonials with Chynna Morgan - June 2024LA HUG - Video Testimonials with Chynna Morgan - June 2024
LA HUG - Video Testimonials with Chynna Morgan - June 2024
Lital Barkan
 
The key differences between the MDR and IVDR in the EU
The key differences between the MDR and IVDR in the EUThe key differences between the MDR and IVDR in the EU
The key differences between the MDR and IVDR in the EU
Allensmith572606
 
Digital Transformation and IT Strategy Toolkit and Templates
Digital Transformation and IT Strategy Toolkit and TemplatesDigital Transformation and IT Strategy Toolkit and Templates
Digital Transformation and IT Strategy Toolkit and Templates
Aurelien Domont, MBA
 
Cree_Rey_BrandIdentityKit.PDF_PersonalBd
Cree_Rey_BrandIdentityKit.PDF_PersonalBdCree_Rey_BrandIdentityKit.PDF_PersonalBd
Cree_Rey_BrandIdentityKit.PDF_PersonalBd
creerey
 
Sustainability: Balancing the Environment, Equity & Economy
Sustainability: Balancing the Environment, Equity & EconomySustainability: Balancing the Environment, Equity & Economy
Sustainability: Balancing the Environment, Equity & Economy
Operational Excellence Consulting
 
Putting the SPARK into Virtual Training.pptx
Putting the SPARK into Virtual Training.pptxPutting the SPARK into Virtual Training.pptx
Putting the SPARK into Virtual Training.pptx
Cynthia Clay
 
Recruiting in the Digital Age: A Social Media Masterclass
Recruiting in the Digital Age: A Social Media MasterclassRecruiting in the Digital Age: A Social Media Masterclass
Recruiting in the Digital Age: A Social Media Masterclass
LuanWise
 
-- June 2024 is National Volunteer Month --
-- June 2024 is National Volunteer Month ---- June 2024 is National Volunteer Month --
-- June 2024 is National Volunteer Month --
NZSG
 
Search Disrupted Google’s Leaked Documents Rock the SEO World.pdf
Search Disrupted Google’s Leaked Documents Rock the SEO World.pdfSearch Disrupted Google’s Leaked Documents Rock the SEO World.pdf
Search Disrupted Google’s Leaked Documents Rock the SEO World.pdf
Arihant Webtech Pvt. Ltd
 
Meas_Dylan_DMBS_PB1_2024-05XX_Revised.pdf
Meas_Dylan_DMBS_PB1_2024-05XX_Revised.pdfMeas_Dylan_DMBS_PB1_2024-05XX_Revised.pdf
Meas_Dylan_DMBS_PB1_2024-05XX_Revised.pdf
dylandmeas
 
Company Valuation webinar series - Tuesday, 4 June 2024
Company Valuation webinar series - Tuesday, 4 June 2024Company Valuation webinar series - Tuesday, 4 June 2024
Company Valuation webinar series - Tuesday, 4 June 2024
FelixPerez547899
 

Recently uploaded (20)

CADAVER AS OUR FIRST TEACHER anatomt in your.pptx
CADAVER AS OUR FIRST TEACHER anatomt in your.pptxCADAVER AS OUR FIRST TEACHER anatomt in your.pptx
CADAVER AS OUR FIRST TEACHER anatomt in your.pptx
 
Evgen Osmak: Methods of key project parameters estimation: from the shaman-in...
Evgen Osmak: Methods of key project parameters estimation: from the shaman-in...Evgen Osmak: Methods of key project parameters estimation: from the shaman-in...
Evgen Osmak: Methods of key project parameters estimation: from the shaman-in...
 
FINAL PRESENTATION.pptx12143241324134134
FINAL PRESENTATION.pptx12143241324134134FINAL PRESENTATION.pptx12143241324134134
FINAL PRESENTATION.pptx12143241324134134
 
Authentically Social Presented by Corey Perlman
Authentically Social Presented by Corey PerlmanAuthentically Social Presented by Corey Perlman
Authentically Social Presented by Corey Perlman
 
Maksym Vyshnivetskyi: PMO Quality Management (UA)
Maksym Vyshnivetskyi: PMO Quality Management (UA)Maksym Vyshnivetskyi: PMO Quality Management (UA)
Maksym Vyshnivetskyi: PMO Quality Management (UA)
 
RMD24 | Debunking the non-endemic revenue myth Marvin Vacquier Droop | First ...
RMD24 | Debunking the non-endemic revenue myth Marvin Vacquier Droop | First ...RMD24 | Debunking the non-endemic revenue myth Marvin Vacquier Droop | First ...
RMD24 | Debunking the non-endemic revenue myth Marvin Vacquier Droop | First ...
 
Enterprise Excellence is Inclusive Excellence.pdf
Enterprise Excellence is Inclusive Excellence.pdfEnterprise Excellence is Inclusive Excellence.pdf
Enterprise Excellence is Inclusive Excellence.pdf
 
Creative Web Design Company in Singapore
Creative Web Design Company in SingaporeCreative Web Design Company in Singapore
Creative Web Design Company in Singapore
 
3.0 Project 2_ Developing My Brand Identity Kit.pptx
3.0 Project 2_ Developing My Brand Identity Kit.pptx3.0 Project 2_ Developing My Brand Identity Kit.pptx
3.0 Project 2_ Developing My Brand Identity Kit.pptx
 
LA HUG - Video Testimonials with Chynna Morgan - June 2024
LA HUG - Video Testimonials with Chynna Morgan - June 2024LA HUG - Video Testimonials with Chynna Morgan - June 2024
LA HUG - Video Testimonials with Chynna Morgan - June 2024
 
The key differences between the MDR and IVDR in the EU
The key differences between the MDR and IVDR in the EUThe key differences between the MDR and IVDR in the EU
The key differences between the MDR and IVDR in the EU
 
Digital Transformation and IT Strategy Toolkit and Templates
Digital Transformation and IT Strategy Toolkit and TemplatesDigital Transformation and IT Strategy Toolkit and Templates
Digital Transformation and IT Strategy Toolkit and Templates
 
Cree_Rey_BrandIdentityKit.PDF_PersonalBd
Cree_Rey_BrandIdentityKit.PDF_PersonalBdCree_Rey_BrandIdentityKit.PDF_PersonalBd
Cree_Rey_BrandIdentityKit.PDF_PersonalBd
 
Sustainability: Balancing the Environment, Equity & Economy
Sustainability: Balancing the Environment, Equity & EconomySustainability: Balancing the Environment, Equity & Economy
Sustainability: Balancing the Environment, Equity & Economy
 
Putting the SPARK into Virtual Training.pptx
Putting the SPARK into Virtual Training.pptxPutting the SPARK into Virtual Training.pptx
Putting the SPARK into Virtual Training.pptx
 
Recruiting in the Digital Age: A Social Media Masterclass
Recruiting in the Digital Age: A Social Media MasterclassRecruiting in the Digital Age: A Social Media Masterclass
Recruiting in the Digital Age: A Social Media Masterclass
 
-- June 2024 is National Volunteer Month --
-- June 2024 is National Volunteer Month ---- June 2024 is National Volunteer Month --
-- June 2024 is National Volunteer Month --
 
Search Disrupted Google’s Leaked Documents Rock the SEO World.pdf
Search Disrupted Google’s Leaked Documents Rock the SEO World.pdfSearch Disrupted Google’s Leaked Documents Rock the SEO World.pdf
Search Disrupted Google’s Leaked Documents Rock the SEO World.pdf
 
Meas_Dylan_DMBS_PB1_2024-05XX_Revised.pdf
Meas_Dylan_DMBS_PB1_2024-05XX_Revised.pdfMeas_Dylan_DMBS_PB1_2024-05XX_Revised.pdf
Meas_Dylan_DMBS_PB1_2024-05XX_Revised.pdf
 
Company Valuation webinar series - Tuesday, 4 June 2024
Company Valuation webinar series - Tuesday, 4 June 2024Company Valuation webinar series - Tuesday, 4 June 2024
Company Valuation webinar series - Tuesday, 4 June 2024
 

Poster - Development of double stand break assessment assay with HCS by using the HepG2 cell line and evaluation with primary skin cell (NHEK)

  • 1. Development of double stand break assessment assay with HCS by using the HepG2 cell line and evaluation with primary skin cell (NHEK) M. ROUDAUT1, S. ASTRI2, N. ORSINI2, A.-P. LUZY2*, J. BURSZTYKA1* & N. MAUBON1 1 HCS Pharma, Biopôle, 6 rue Pierre Joseph Colin, 35000 Rennes 1* julian.bursztyka@hcs-pharma.com 2 Galderma R&D, Les Templiers, 2400 route des Colles, 06410 Biot ²*anne-pascale.luzy@galderma.com Abstract The creation of a double strand break (DSB) is accompanied by the phosphorylation of histone H2AX. The measurement of serine 139 phosphorylated histone H2AX (γH2AX) is reported to be a marker of interest to identify potential genotoxic activity. In order to evaluate the High Content Screening for γH2AX detection, 4 non genotoxic compounds and 9 genotoxic compounds from the ECVAM list I or II were selected to to be tested on HepG2 cell line. These cells offer the advantage to have H2AX expression data in the literature. In parallel, Human primary keratinocytes were included. Indeed these cells would be relevant for investigating skin adverse effects of topical applied xenobiotics with the advantage of High content imaging as valuable tool for screening in the early discovery phase. Methods Conclusions & Perspectives Cell culture: HepG2 were routinely maintained in MEM supplemented with 10% FBS, 1% non essential amino-acids, 1% peni/strepto and 1% L-glutamine. Neonatal human epidermal keratinocytes (NHEK, pool of donors) were obtained and cultured following the recommendations from Lonza. Cells were seeded at 10 000 cells/well for HepG2 and 5 000 cells/well for NHEK in 96-well plates (Greiner® advanced TC µClear). The cells were then incubated overnight at 37 °C in 5 % CO2 before treatment. Genotoxic drugs exposure: 16 compounds were assessed for their DSBs inducing properties: Etoposide, azidothymidine (AZT), mitomycine C (MMC), vinblastin, taxol, colchicine, methylmethane sulfonate (MMS), N-ethyl-N-nitrosourea (ENU), Cisplatin, 4-nitroquinoline-N-oxide (4NQO), Phenformin, cadmium chloride, hydroquinone, D-mannitol, ampicilline & n-butyl chloride. Exposure of the cells was performed by replacement of the medium in each well with fresh medium with or without the different genotoxic agents at different concentrations ranging from 0.195 µM to 100 µM, except for MMS and ENU (1.563 to 1000µM). Benzo-[a]-pyren (BaP, 10µM, genotoxic only if metabolized) and MMC (10µM) were used as positive controls. Incubations were done in duplicate. Assessment of double strand breaks through γH2AX detection: Cells were paraformaldehyde fixed (4%) after 24h of exposure. After permeabilisation of the cells by PBS/Tween20, staining was done by adding anti-γH2AX (phospho ser139) antibody (Abcam) followed by secondary antibody conjugated with Alexa-488. Nuclei were counterstained with Hoechst 33348. Imaging was done on an Operetta (Perkin Elmer) with a 20x objective. Image analysis was performed with Columbus software (Perkin Elmer). Relative cell count (RCC) was calculated as a percentage of the cell count in the control (0.5% DMSO). For γH2AX Results are expressed as a fold change of the mean intensity in the nucleus γH2AX intensity is significantly higher than the untreated cells. To get this poster, please flash the QR- code You can use the I-NIGMA application from your store  Evaluation of γH2AX by HCS on HepG2 and Primary Human keratinocytes cells seems to be a promising technology.  On Primary Human keratinocytes different technical aspect have to be improved (i.e. cell synchronization) to generate robust results and more compounds have to be tested.  The RCC cut off and the γH2AX positive threshold have to be accurately defined.  Further work is needed on both cell types to fully validate the use of HCS for γH2AX assessment. Results Fig. 1: Inter and intra plate variability on HepG2 cells. Fig. 2: Genotoxicity (γH2AX ) and cytotoxicity (RCC) assessment on HepG2 cells. Example of data. Fig. 3: Comparison of the sensitivity and specificity of HepG2 as a cellular model to screen compounds for their DSBs inducing properties. Fig. 4: Development of this assay on human primary keratinocytes. Fig. 5: Nuclei of primary human epidermal keratinocytes exposed to etoposide 6.25µM for 24h. Blue : Hoechst staining. Green : γH2AX staining (a). Red: 53BP1 staining (b). P53 binding protein 1 is involved in the DSBs repair process, thus colocalising with γH2AX (c : merged images). a b c